Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention

Author(s): Ali Ali, Pierluigi Costanzo and Angela Hoye*

Volume 24, Issue 4, 2018

Page: [442 - 450] Pages: 9

DOI: 10.2174/1381612824666180111105201

Price: $65

Abstract

Elevated levels of Low Density Lipoprotein cholesterol (LDL-C) are directly associated with increased risk for atherosclerotic cardiovascular and cerebrovascular events. Statins have been used to control serum LDLC and this has translated into reduction in cardiovascular and cerebrovascular events. However, despite high dose statin therapy, LDL-C control may remain inadequate in some patients, particularly those with familial hypercholesterolemia. A new therapeutic approach has emerged in recent years with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.

In this review, we describe the development and the use of this new class of drugs.

Keywords: Cholesterol, LDL, PCSK9 inhibitors, statins, serum LDL-C, hypercholesterolemia.

« Previous Next »

Rights & Permissions Print Cite
Article Metrics
23
3
1
1
© 2025 Bentham Science Publishers | Privacy Policy